Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693

Por Kumar, Rakesh, Blakemore, Stephen J, Ellis, Catherine E, Petricoin, Emanuel F, Pratt, Dexter, Macoritto, Michael, Matthews, Andrea L, Loureiro, Joseph J, Elliston, Keith
Publicado em 2010

Targeting the Protein Ubiquitination Machinery in Melanoma by the NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924)

Por Wong, Kit Man, Micel, Lindsey N., Selby, Heather M., Tan, Aik Choon, Pitts, Todd M., Bagby, Stacey M., Spreafico, Anna, Klauck, Peter J., Blakemore, Stephen J., Smith, Peter F., McDonald, Alice, Berger, Allison, Tentler, John J., Eckhardt, S. Gail
Publicado no Invest New Drugs (2016)

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Por Mulligan, George, Lichter, David I., Di Bacco, Alessandra, Blakemore, Stephen J., Berger, Allison, Koenig, Erik, Bernard, Hugues, Trepicchio, William, Li, Bin, Neuwirth, Rachel, Chattopadhyay, Nibedita, Bolen, Joseph B., Dorner, Andrew J., van de Velde, Helgi, Ricci, Deborah, Jagannath, Sundar, Berenson, James R., Richardson, Paul G., Stadtmauer, Edward A., Orlowski, Robert Z., Lonial, Sagar, Anderson, Kenneth C., Sonneveld, Pieter, San Miguel, Jesús F., Esseltine, Dixie-Lee, Schu, Matthew
Publicado em 2014